HIMS
Another day, another peptide pop
Hims & Hers is catching a bid Monday because traders think the FDA might make life a little easier for compounded peptide therapies. Translation: if regulators loosen up, Hims could have a cleaner runway for one of the spicier parts of its telehealth growth story.
Why the market cares
The company is staring down a July 23–24 FDA meeting that will review seven peptide compounds, including BPC-157, for possible inclusion on the list of substances compounding pharmacies can legally make. That matters because the FDA already tightened the screws in 2023, and investors have been treating every hint of policy softening like it’s a Marvel post-credits scene.
Not just vibes, though
Hims has also been building for this moment the boring way — by buying a factory in February to make peptides itself. So if the regulatory backdrop improves, it’s not just a nice headline; it could help the company scale a product line that sits right at the intersection of telehealth, wellness, and “please let this not become a compliance headache.”
The stock still has plenty of opinions
BofA adding a higher price target doesn’t hurt either, even if the firm kept its Neutral rating. Meanwhile, the stock is already running hot, so you’ve got the classic combo of optimism, momentum buyers, and a stock that’s one sharp pullback away from reminding everyone gravity still exists.
Big picture: if the FDA gives Hims a friendlier lane on peptides, the bull case gets a lot less theoretical — and a lot more investable.